Short Summary
Plaintiffs filed a suit seeking permanent injunction against Natco Pharma for infringing Indian Patent No.IN247381 (APIXABAN). The defendant sought a stay under Section 10 CPC, citing a previously instituted suit in the City Civil Court at Hyderabad concerning patent validity and infringement. The High Court dismissed the stay application.
Detailed Summary
In the high-stakes world of pharmaceutical patents, choosing the right courtroom can be just as important as choosing the right lawyer. When a global innovator and a domestic challenger both race to file suits over the same molecule, the law must decide whose fight gets heard first. This case between Bristol Myers Squibb Holdings Ireland and Natco Pharma is a masterclass in how Indian courts handle that exact collision.
Bristol Myers Squibb Holdings Ireland, the holder of Indian Patent No. IN247381 covering APIXABAN, found itself in a dispute with Natco Pharma over alleged infringement of that patent. Seeking to protect its intellectual property, Bristol Myers Squibb filed a suit for a permanent injunction against Natco Pharma. However, Natco Pharma had already instituted a separate suit in the City Civil Court at Hyderabad concerning the very same patent, raising questions about both its validity and infringement. This overlap set the stage for a jurisdictional tug-of-war.
Natco Pharma leaned on Section 10 of the Code of Civil Procedure, arguing that the previously filed suit in the City Civil Court at Hyderabad should take precedence. The defendant's position was rooted in the principle that once a court has been approached first, subsequent suits involving the same subject matter should be stayed to avoid conflicting decisions. Bristol Myers Squibb, on the other hand, pushed back against the stay application, contending that allowing the City Civil Court to entertain the matter would result in a fragmented and inefficient adjudication of all the disputes between the parties.
The High Court sided with Bristol Myers Squibb and dismissed Natco Pharma's stay application. The court made it clear that Section 10 of the CPC is not a mandatory provision that must be mechanically applied in every case. Where entertaining a particular suit would lead to a composite adjudication of all disputes between the parties, the court has the discretion to disregard the stay request. By refusing to halt its own proceedings, the High Court ensured that the patent dispute could be resolved in a single, coherent forum rather than being splintered across multiple courts.
For founders, startup leaders, and IP professionals, the lesson is strategic and immediate: filing first does not guarantee you control the battlefield. If a competitor tries to use a prior suit to block your infringement action, remember that courts have the power to refuse a stay when doing so would cause piecemeal justice. Build your litigation strategy around the strength of your forum, not just the speed of your filing, and be prepared to argue why a unified adjudication serves the interests of justice better than a procedural technicality.
Practitioner Note
This case demonstrates the evidentiary and procedural standards applied in patent matters before Delhi High Court. Understanding the court's reasoning in Bristol Myers Squibb Holdings Ireland Unlimited Company vs Natco Pharma is valuable context for structuring arguments or assessing risk in similar proceedings.
Related Cases
Sun Pharma Laboratories LtdvsLupin Ltd & Anr
The Delhi High Court confirmed an interim injunction in favor of Sun Pharma Laboratories Ltd against Lupin Ltd and others. The court found that the defendant's trade mark, TRI-VOBIT, was structurally and phonetically similar to the plaintiff’s registered mark, TRIVOLIB. Despite arguments regarding prior use of 'VOBIT,' the court ruled that the full marks must be compared, establishing a prima facie case for trademark infringement and passing off.
Jagdish Pershad LaddavsIntellectual Property Appellate Board (and others)
The Telangana High Court dismissed a long-pending writ petition challenging an earlier trademark registration order. The dispute involved two parties claiming rights to the 'Super XTRA' mark for detergent products, with one party having filed their application significantly earlier than the other. Given that over sixteen years had passed since the initial filing of the writ petition, the court found the challenge infructuous and declined to disturb the established trademark registration.
Ischemix LlcvsThe Controller Of Patents
Ischemix Llc appealed the rejection of its Indian Patent Application No.4380/DELNP/2013 by the Controller of Patents, which was based on Section 3(d) of the Patents Act, 1970. The appellant challenged the basis and citation of the prior art documents used against them.
Chugai Seiyaku Kabushiki KaishavsHetero Labs Limited
The Plaintiffs filed a suit seeking permanent injunction and damages against the Defendants for infringing Indian Patent No. 294424, which covers the tetracyclic compound Alectinib used in cancer treatment. The dispute centered on whether the Defendant's import and use of Alectinib Hydrochloride were commercial infringements or activities permitted under Section 107A (Bolar provision) for research and regulatory purposes.
Ashok Kumar Gupta & Anr.vsRishabh Bansal & Anr.
The Delhi High Court disposed of a complex IP dispute involving trademark infringement, copyright violation, and rectification petitions between Ashok Kumar Gupta and Rishabh Bansal. The parties reached a comprehensive settlement agreement mediated by the court. Under the terms, the defendant acknowledged the plaintiffs' proprietary rights in the 'SAKARNI' brand (trademark) and its packaging features (copyright). The defendant committed to withdrawing an infringing mark, ceasing all use of similar marks/designs, and paying substantial damages.
Dealing with a patent challenge?
Whether it's a Section 3(d) rejection, a post-grant opposition, or a FRAND dispute, Arctic's patent litigation team has handled it. Get a strategy call.
Disclaimer: This page contains an automated summary based on publicly available judicial records. The content is generated for informational purposes only and does not constitute legal advice. Always verify details against the original source judgment before relying on this information for any legal purpose. If you believe any information is inaccurate, please contact us.